Mustophoran (Fotemustine)

Fotemustine, the active ingredient in Mustophoran, is a nitrosourea alkylating agent presented as an intravenous formulation for use in oncology. It is employed to treat malignant melanoma and high‑grade glioma, targeting rapidly dividing tumor cells in adult patients.

GNH USA supplies Mustophoran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Fotemustine is used in oncology to address aggressive solid tumours that are responsive to alkylating chemotherapy.

Malignant melanoma: provides disease control and may extend survival in advanced cases. High‑grade glioma: used as part of a chemotherapy regimen to reduce tumour burden. Recurrent glioma: employed when standard therapies have failed to achieve adequate response.

Fotemustine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting - Fatigue or weakness - Myelosuppression (decreased blood cell counts) - Alopecia (hair loss) - Elevated liver enzymes - Mild fever or chills

Serious or Rare Side Effects: - Severe bone‑marrow suppression leading to infection or bleeding - Pulmonary fibrosis or interstitial lung disease - Acute hepatic failure - Life‑threatening allergic reactions (anaphylaxis) - Seizures or neurological toxicity - Secondary malignancies

When using Fotemustine, clinicians should observe several safety measures.

Monitor blood counts: perform regular complete blood count assessments. Assess liver function: check hepatic enzymes before and during therapy. Evaluate pulmonary status: screen for pre‑existing lung disease. Avoid in patients with known hypersensitivity to nitrosoureas. Use caution in renal impairment: adjust monitoring frequency. Store at ambient temperature: keep in original packaging, protect from moisture and light.

Fotemustine can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Concurrent use with other alkylating agents (excessive bone‑marrow toxicity) - Combination with radiotherapy (enhanced tissue damage) - Co‑administration with strong myelosuppressive drugs (risk of severe cytopenia)

Moderate Interactions (Monitor Closely): - Anticonvulsants that induce hepatic enzymes (may reduce efficacy) - Non‑steroidal anti‑inflammatory drugs (increase bleeding risk) - Warfarin (potential alteration of anticoagulant effect)